Opinion Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jul 7, 2021; 27(25): 3693-3704
Published online Jul 7, 2021. doi: 10.3748/wjg.v27.i25.3693
Table 1 Table of trials evaluating ideal cut off value for infliximab and adalimumab concentrations
Ref.
Population (adults or children)
Number
Study design
Follow up or time on therapy
Outcomes
Median level
Median level
Trial: Infliximab
Plevris et al[43]Adult29Retrospective single center cross sectional2.6 yrFistula healing; Fistula closure8.1; 8.23.2; 3.2
Strik et al[40]Adult47Retrospective single centercross sectional3.5 yrFistula closure6.02.3
Davidov et al[44]Adult36Retrospective observational two centersWeek 2; Week 6; Week 14Decrease or cessation of fistula drainage at week 1420; 13.3; 4.15.6; 2.55; 0.14
Zhu et al[69]Adult157Retrospective single centerWeek 30; Week 78; Week 116Radiological remission (absence of high-signal tracks on fat-saturated T2-weighted sequences)3.5; 2.85; 2.841.9; 1.63; 0.7
El-Matary et al[42]Pediatric85Prospective observational 12 centersWeek 14Clinical fistula healing at week 2412.75.4
Yarur et al[39]Adult117Retrospective, cross sectional, 2 centers29 wkFistula healing15.84.4
Trial: Adalimumab
Plevris et al[43]Adult35Retrospective single center cross sectional1.7 yrFistula healing; Fistula closure14.8; 12.65.7; 2.7
Strik et al[40]Adult19Retrospective single center cross sectional3.5 yrFistula closure7.44.8
Ruemmele et al[41]Pediatric36Randomized control trialWeek 16; Week 52Clinical fistula closure7.4; 7.56.4; 5.6